Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders

Details for Australian Patent Application No. 2006272937 (hide)

International Classifications

Event Publications

7 February 2008 PCT application entered the National Phase

PCT publication WO2007/013944 Priority application(s): WO2007/013944

28 February 2008 Corrigenda

PCT applications that have entered the National Phase - Name Index Under the name Zymogenetics, Inc., Application No. 2006272937, Under INID (71) corrected the applicant name to ZymoGenetics, Inc.

8 October 2009 Assignment before Grant

ZymoGenetics, Inc. The application has been assigned to Bristol-Myers Squibb Company; ZymoGenetics, Inc.

3 June 2010 Corrigenda

Assignments Before Grant, Section 113 - 2006 Delete all reference to Application No. 2006272937

9 September 2010 Alteration of Name

The name of the applicant has been altered to ZymoGenetics, LLC; Bristol-Myers Squibb Company

16 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.